Authors: Akashi, Takuya; Koizumi, Keiichi¹; Tsuneyama, Koichi²; Saiki, Ikuo; Takano, Yasuo²; Fuse, Hideki³

Source: Cancer Science, Volume 99, Number 3, March 2008 , pp. 539-542(4)

Publisher: Wiley-Blackwell

Abstract:

The chemokine receptor CXCR4 has been reported to be aberrantly expressed in human cancers and has also been shown to participate in the development of cancer metastasis. The present study was carried out to assess immunohistochemically the pattern of CXCR4 expression in patients with metastatic prostate cancer. We analyzed whether there may be an association between CXCR4 expression and prognosis. Fifty-two patients who received hormonal therapy were enrolled. Specimens were obtained from transperineal needle biopsy before treatment, and were stained with antihuman CXCR4 antibody. We also evaluated the pathological grade, extent of bony metastasis, clinical response to hormonal therapy, and patient prognosis. CXCR4 was detected in 94.2% patients. Its expression showed no association with pathological grade, extent of bony metastasis, or clinical response to hormonal therapy. Patients with a high expression of CXCR4 in tumors had poorer cancer-specific survival than those with low expression of CXCR4. CXCR4 expression is a useful prognostic factor for patients with metastatic prostate cancer treated with androgen-withdrawal therapy. (Cancer Sci 2008; 99: 539-542)

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1349-7006.2007.00712.x

Affiliations: 1: Division of Pathogenic Biochemistry, Department of Bioscience, Institute of Natural Medicine; 2: Department of Pathology, Graduate School of Medicine and Pharmaceutical Sciences for Research; 3: Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research;

Publication date: 2008-03-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Oncology
• By this author: Akashi, Takuya ;  Koizumi, Keiichi ;  Tsuneyama, Koichi ;  Saiki, Ikuo ;  Takano, Yasuo ;  Fuse, Hideki

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers